# Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa

> **NCT00638365** · PHASE1,PHASE2 · COMPLETED · sponsor: **Humanigen, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **BIOLOGICAL:** KB001
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00638365
- **Lead sponsor:** Humanigen, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2009-03
- **Final completion:** 2009-04
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2014-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00638365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00638365, "Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00638365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*